SB939 compound clinical trials
Also written SB939 and Pracinostat.
How each study uses SB939 compound is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
15 studies that test it; most in 2010 (4)
| Year | Studies |
|---|---|
| 2007 | 2 |
| 2010 | 4 |
| 2013 | 3 |
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 7
Helsinn Healthcare SA (7) · NCIC Clinical Trials Group (4) · M.D. Anderson Cancer Center (2) · Medical College of Wisconsin (1) · S*BIO (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of HDAC inhibitors source
Studies
Open first, then newest update. How each study uses SB939 compound is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 15
- A Phase I Study of SB939 in Pediatric Patients With Refractory Solid Tumours and LeukemiaCompletedPhase 1NCIC Clinical Trials GroupNCT01184274Written as SB939How we know
- SB939 in Treating Patients With Locally Advanced or Metastatic Solid TumorsCompletedPhase 1NCIC Clinical Trials GroupNCT00504296Written as HDAC inhibitor SB939How we know
- SB939 in Treating Patients With Recurrent or Metastatic Prostate CancerCompletedPhase 2NCIC Clinical Trials GroupNCT01075308Written as HDAC inhibitor SB939How we know
- A Study of SB939 in Patients With Translocation-Associated Recurrent/Metastatic SarcomasCompletedPhase 2NCIC Clinical Trials GroupNCT01112384Written as SB939How we know
- Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid LeukemiaCompletedPhase 1Medical College of WisconsinNCT03848754Written as Pracinostat - 45 mgHow we know
- An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid LeukemiaTerminatedPhase 3Helsinn Healthcare SANCT03151408Written as PracinostatHow we know
- A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic SyndromesTerminatedPhase 2Helsinn Healthcare SANCT03151304Written as PracinostatHow we know
- Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)CompletedPhase 2Helsinn Healthcare SANCT01912274Written as PracinostatHow we know
- A Study In Healthy Male Volunteers Designed To Investigate How A Radiolabelled Medicine Is Broken Down And Removed From The BodyCompletedPhase 1Helsinn Healthcare SANCT03495934Written as pracinostatHow we know
- Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)CompletedPhase 2M.D. Anderson Cancer CenterNCT02267278Written as PracinostatHow we know
- Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic SyndromeCompletedPhase 2Helsinn Healthcare SANCT01873703Written as pracinostatHow we know
- Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMACompletedPhase 2Helsinn Healthcare SANCT01993641Written as pracinostatHow we know
- Study to Evaluate the Food Effect of Single-dose Bioavailability of Pracinostat in Healthy Adult SubjectsCompletedEarly Phase 1Helsinn Healthcare SANCT02058784Written as pracinostatHow we know
- Study of SB939 in Subjects With MyelofibrosisCompletedPhase 2M.D. Anderson Cancer CenterNCT01200498Written as SB939How we know
- A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With AzacitidineCompletedPhase 1S*BIONCT00741234Written as SB939How we know